This forum thread will be used by the Beacon Staff to post updates about the proceedings of the American Society of Hematology (ASH) meeting taking place on Day 4 (Tuesday, December 13) of the conference.
Beacon forum participants are free, however, to use this thread to comment on the updates, post their own updates or thoughts, and ask questions. Everyone is encouraged to participate.
Feel free to also check out the threads dedicated to Day 1, Day 2, and Day 3 of the ASH 2011 meeting.
For an earlier discussion of ASH 2011 presentation and poster abstracts, please see this thread:
https://myelomabeacon.org/forum/ash-2011-annual-meeting-multiple-myeloma-t692.html
Forums
2 posts
• Page 1 of 1
Re: ASH 2011 Multiple Myeloma Discussion - Day 4
There was one session this morning with a number of key myeloma-related presentations. We'll outline what the presentations were and share some key points, then double back later today or tomorrow with more details about each presentation.
The first presentation was by Dr. María-Victoria Mateos from the University Hospital in Salamanca, Spain. She reported on a trial she and her colleagues are doing on the treatment of high-risk smoldering myeloma patients with Revlimid and dexamethasone.
She and her colleagues have found that treatment of high-risk smoldering myeloma patients with Revlimid and dexamethasone delays the progression of these patients to active myeloma.
Abstract: http://ash.confex.com/ash/2011/webprogram/Paper40382.html
The second presentation was by Dr. Gareth Morgan of the Institute of Cancer Research in London. He reported the latest updated results, based on a six-year follow-up, of the so-called Myeloma IX trial -- the largest multiple myeloma trial every conducted.
The follow-up mainly confirmed findings previously reported using this same dataset. (And as the study was large and had a complex design, the results really can't be summarized briefly here!)
Abstract: http://ash.confex.com/ash/2011/webprogram/Paper42678.html
Dr. Hervé Avet-Loiseau of the Central University Hospital of Nantes, France, presented next. He described a retrospective analysis conducted by the summarized the results of a French study looking at the prevalence and impact of chromosomal abnormalities in older multiple myeloma patients (that is, those over 65 years of age).
The study confirmed findings of research with younger myeloma patients that the abnormalities t(4;14) and del(17p) negatively impact both progression free survival and overall survival in older myeloma patients.
Abstract: http://ash.confex.com/ash/2011/webprogram/Paper38835.html
The final presentation of the morning was by Dr. Antonio Palumbo of the University of Torino, Italy. He summarized the results of a retrospective analysis designed to measure and better describe the risk of secondary cancer associated with Revlimid or thalidomide treatment.
He found that there is an increased risk of secondary cancer associated with Revlimid treatment, and there also seems to be a risk of a similar magnitude associated with thalidomide treatment.
However, the risk is seen mainly in patients who also have been treated with melphalan. Patients who have been treated with Revlimid, but have not been treated with melphalan, have about half the risk of developing secondary cancers compared to patients treated with both Revlimid and melphalan.
Abstract: http://ash.confex.com/ash/2011/webprogram/Paper37311.html
The first presentation was by Dr. María-Victoria Mateos from the University Hospital in Salamanca, Spain. She reported on a trial she and her colleagues are doing on the treatment of high-risk smoldering myeloma patients with Revlimid and dexamethasone.
She and her colleagues have found that treatment of high-risk smoldering myeloma patients with Revlimid and dexamethasone delays the progression of these patients to active myeloma.
Abstract: http://ash.confex.com/ash/2011/webprogram/Paper40382.html
The second presentation was by Dr. Gareth Morgan of the Institute of Cancer Research in London. He reported the latest updated results, based on a six-year follow-up, of the so-called Myeloma IX trial -- the largest multiple myeloma trial every conducted.
The follow-up mainly confirmed findings previously reported using this same dataset. (And as the study was large and had a complex design, the results really can't be summarized briefly here!)
Abstract: http://ash.confex.com/ash/2011/webprogram/Paper42678.html
Dr. Hervé Avet-Loiseau of the Central University Hospital of Nantes, France, presented next. He described a retrospective analysis conducted by the summarized the results of a French study looking at the prevalence and impact of chromosomal abnormalities in older multiple myeloma patients (that is, those over 65 years of age).
The study confirmed findings of research with younger myeloma patients that the abnormalities t(4;14) and del(17p) negatively impact both progression free survival and overall survival in older myeloma patients.
Abstract: http://ash.confex.com/ash/2011/webprogram/Paper38835.html
The final presentation of the morning was by Dr. Antonio Palumbo of the University of Torino, Italy. He summarized the results of a retrospective analysis designed to measure and better describe the risk of secondary cancer associated with Revlimid or thalidomide treatment.
He found that there is an increased risk of secondary cancer associated with Revlimid treatment, and there also seems to be a risk of a similar magnitude associated with thalidomide treatment.
However, the risk is seen mainly in patients who also have been treated with melphalan. Patients who have been treated with Revlimid, but have not been treated with melphalan, have about half the risk of developing secondary cancers compared to patients treated with both Revlimid and melphalan.
Abstract: http://ash.confex.com/ash/2011/webprogram/Paper37311.html
2 posts
• Page 1 of 1